These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35195572)

  • 1. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS.
    O'Donnell MR; Padayatchi N; Wolf A; Zelnick J; Daftary A; Orrell C; Nimmo C; Baldwin M; Boodhram R; Maharaj B; Amico KR; Naidoo K; Friedland G
    J Acquir Immune Defic Syndr; 2022 Jul; 90(3):325-332. PubMed ID: 35195572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis.
    Bateman M; Wolf A; Chimukangara B; Brust JCM; Lessells R; Amico R; Boodhram R; Singh N; Orrell C; Friedland G; Naidoo K; Padayatchi N; O'Donnell MR
    Clin Infect Dis; 2022 Oct; 75(9):1489-1496. PubMed ID: 35352097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.
    Bionghi N; Daftary A; Maharaj B; Msibi Z; Amico KR; Friedland G; Orrell C; Padayatchi N; O'Donnell MR
    BMC Infect Dis; 2018 Apr; 18(1):171. PubMed ID: 29642874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial.
    Ross J; Perumal R; Wolf A; Zulu M; Guzman K; Seepamore B; Reis K; Nyilana H; Hlathi S; Narasimmulu R; Cheung YKK; Amico KR; Friedland G; Daftary A; Zelnick JR; Naidoo K; O'Donnell MR
    Trials; 2023 Dec; 24(1):776. PubMed ID: 38037105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency Virus.
    Zelnick JR; Daftary A; Hwang C; Labar AS; Boodhram R; Maharaj B; Wolf AK; Mondal S; Amico KR; Orrell C; Seepamore B; Friedland G; Padayatchi N; O'Donnell MR
    Clin Infect Dis; 2021 Oct; 73(7):e1901-e1910. PubMed ID: 33053186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decentralized, Integrated Treatment of RR/MDR-TB and HIV Using a Bedaquiline-Based, Short-Course Regimen Is Effective and Associated With Improved HIV Disease Control.
    Govender T; Jham MA; Zhang JC; Pillay S; Pak Y; Pillay P; Furin J; Malenfant J; Murphy RA
    J Acquir Immune Defic Syndr; 2023 Apr; 92(5):385-392. PubMed ID: 36729541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): Study protocol for an adaptive randomized controlled trial.
    Ross JE; Perumal R; Wolf A; Zulu M; Guzman K; Seepamore B; Reis K; Nyilana H; Hlathi S; Narasimmulu R; Cheung YKK; Amico KR; Friedland G; Daftary A; Zelnick J; Naidoo K; O'Donnell MR
    Res Sq; 2023 Jun; ():. PubMed ID: 37333087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
    Zhao Y; Fox T; Manning K; Stewart A; Tiffin N; Khomo N; Leslie J; Boulle A; Mudaly V; Kock Y; Meintjes G; Wasserman S
    Clin Infect Dis; 2019 Apr; 68(9):1522-1529. PubMed ID: 30165431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Antiretroviral Therapy on Treatment Outcomes in a Prospective Study of Extensively Drug-Resistant Tuberculosis (XDR-TB) HIV Coinfection Treatment in KwaZulu-Natal, South Africa.
    Yuengling KA; Padayatchi N; Wolf A; Mathema B; Brown T; Horsburgh CR; OʼDonnell MR
    J Acquir Immune Defic Syndr; 2018 Dec; 79(4):474-480. PubMed ID: 30212394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
    Chesov D; Heyckendorf J; Alexandru S; Donica A; Chesov E; Reimann M; Crudu V; Botnaru V; Lange C
    Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33334942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 15. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.
    Nimmo C; Millard J; van Dorp L; Brien K; Moodley S; Wolf A; Grant AD; Padayatchi N; Pym AS; Balloux F; O'Donnell M
    Lancet Microbe; 2020 Aug; 1(4):e165-e174. PubMed ID: 32803174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
    Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid.
    Padayatchi N; Bionghi N; Osman F; Naidu N; Ndjeka N; Master I; Brust JCM; Naidoo K; Ramjee A; O Donnell M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1024-1031. PubMed ID: 33126934
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed Opportunity.
    Geiger K; Patil A; Budhathoki C; Dooley KE; Lowensen K; Ndjeka N; Ngozo J; Farley JE
    J Acquir Immune Defic Syndr; 2023 Nov; 94(3):253-261. PubMed ID: 37757847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    Kunkel A; Cobelens FG; Cohen T
    PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.